+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Uveitis - Pipeline Review, H2 2018

  • ID: 4621776
  • Drug Pipelines
  • 207 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aciont Inc
  • Bristol-Myers Squibb Co
  • Enzo Biochem Inc
  • Galapagos NV
  • Kv1.3 Therapeutics
  • Novartis AG
  • MORE
Uveitis - Pipeline Review, H2 2018

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2018, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

This latest pipeline guide Uveitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 8, 6, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aciont Inc
  • Bristol-Myers Squibb Co
  • Enzo Biochem Inc
  • Galapagos NV
  • Kv1.3 Therapeutics
  • Novartis AG
  • MORE
Introduction

Uveitis - Overview

Uveitis - Therapeutics Development

Uveitis - Therapeutics Assessment

Uveitis - Companies Involved in Therapeutics Development

Uveitis - Drug Profiles

Uveitis - Dormant Projects

Uveitis - Discontinued Products

Uveitis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Uveitis - Pipeline by Aciont Inc, H2 2018

Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2018

Uveitis - Pipeline by Alvotech Iceland, H2 2018

Uveitis - Pipeline by Apitope International NV, H2 2018

Uveitis - Pipeline by Bristol-Myers Squibb Co, H2 2018

Uveitis - Pipeline by Clearside BioMedical Inc, H2 2018

Uveitis - Pipeline by Coherus BioSciences Inc, H2 2018

Uveitis - Pipeline by Elasmogen Ltd, H2 2018

Uveitis - Pipeline by Enzo Biochem Inc, H2 2018

Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Uveitis - Pipeline by EyePoint Pharmaceuticals Inc, H2 2018

Uveitis - Pipeline by Eyevensys SAS, H2 2018

Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Uveitis - Pipeline by Fresenius SE & Co KGaA, H2 2018

Uveitis - Pipeline by Galapagos NV, H2 2018

Uveitis - Pipeline by HanAll Biopharma Co Ltd, H2 2018

Uveitis - Pipeline by Idera Pharmaceuticals Inc, H2 2018

Uveitis - Pipeline by Johnson & Johnson, H2 2018

Uveitis - Pipeline by Kv1.3 Therapeutics, H2 2018

Uveitis - Pipeline by Midatech Pharma Plc, H2 2018

Uveitis - Pipeline by Mitotech SA, H2 2018

Uveitis - Pipeline by Nemus Bioscience Inc, H2 2018

Uveitis - Pipeline by Novartis AG, H2 2018

Uveitis - Pipeline by OncoNOx ApS, H2 2018

Uveitis - Pipeline by Ophthotech Corp, H2 2018

Uveitis - Pipeline by Orchid Pharma Ltd, H2 2018

Uveitis - Pipeline by Palatin Technologies Inc, H2 2018

Uveitis - Pipeline by Panoptes Pharma GesmbH, H2 2018

Uveitis - Pipeline by Re-Pharm Ltd, H2 2018

Uveitis - Pipeline by Sandoz International GmbH, H2 2018

Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H2 2018

Uveitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Uveitis - Dormant Projects, H2 2018

Uveitis - Dormant Projects, H2 2018 (Contd..1), H2 2018

Uveitis - Dormant Projects, H2 2018 (Contd..2), H2 2018

Uveitis - Dormant Projects, H2 2018 (Contd..3), H2 2018

Uveitis - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aciont Inc
  • Aldeyra Therapeutics Inc
  • Alvotech Iceland
  • Apitope International NV
  • Bristol-Myers Squibb Co
  • Clearside BioMedical Inc
  • Coherus BioSciences Inc
  • Elasmogen Ltd
  • Enzo Biochem Inc
  • EyeGate Pharmaceuticals Inc
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • F. Hoffmann-La Roche Ltd
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • HanAll Biopharma Co Ltd
  • Idera Pharmaceuticals Inc
  • Johnson & Johnson
  • Kv1.3 Therapeutics
  • Midatech Pharma Plc
  • Mitotech SA
  • Nemus Bioscience Inc
  • Novartis AG
  • OncoNOx ApS
  • Ophthotech Corp
  • Orchid Pharma Ltd
  • Palatin Technologies Inc
  • Panoptes Pharma GesmbH
  • Re-Pharm Ltd
  • Sandoz International GmbH
  • Santen Pharmaceutical Co Ltd
  • Sun Pharma Advanced Research Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4621776
Adroll
adroll